All In Biotech

Drug Trial Radar · NCT05315700

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Mar 10, 2022

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
ORIC PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Conditions

  • Solid Tumors

Interventions

  • ORIC-114Drug

    ORIC-114 oral daily

  • Chemotherapy drugDrug

    21 days for up to 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D)Time frame: 12 months
  2. Maximum plasma concentration (Cmax)Time frame: 28 Days
  3. Time of maximum observed concentration (Tmax)Time frame: 28 Days
  4. Area under the curve (AUC)Time frame: 28 Days
  5. Apparent plasma terminal elimination half-life (t1/2)Time frame: 28 Days

Locations

42 sites in 10 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope

    Huntington Beach, California · Recruiting

  • City of Hope

    Irvine, California · Recruiting

  • City of Hope

    Long Beach, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Spartanburg Regional Healthcare System

    Spartanburg, South Carolina · Recruiting

  • Next Oncology

    Fairfax, Virginia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • One Clinical Research, Hollywood Medical Centre

    Nedlands, Australia · Recruiting

  • Sydney Adventist Health

    Sydney, Australia · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • The Chinese University of Hong Kong

    Shatin, Hong Kong · Recruiting

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia · Recruiting

  • University of Malaya Medical Center (UMMC)

    Kuala Lumpur, Malaysia · Recruiting

  • Sultan Ahmad Shah Medical Centre at International Islamic University Malaysia (IIUM)

    Kuantan, Pahang, Malaysia · Recruiting

  • Pulau Pinang Hospital

    George Town, Pulau Pinang, Malaysia · Recruiting

  • Sarawak General Hospital (SGH)

    Kuching, Sarawak, Malaysia · Recruiting

  • Medical University of Gdańsk

    Gdansk, Poland · Recruiting

  • Chungbuk University Hospital

    Cheongju-si, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, South Korea · Recruiting

  • Catholic University of Korea, St, Vincent Hospital

    Gyeonggi-do, South Korea · Recruiting

  • Gachon University Hospital

    Incheon, South Korea · Recruiting

  • Seoul National Bundang Hospital

    Seongnam-si, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • NEXT Oncology - Barcelona

    Barcelona, Spain · Recruiting

  • Vall d'Hebron Institute of Oncology (VHIO)

    Barcelona, Spain · Recruiting

  • NEXT Oncology - Madrid

    Madrid, Spain · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.